Othman Al-Sawaf (O Al-Sawaf)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Venues

American journal of hematology

Leukemia

Nature medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology 99 (6) (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Arnon P Kater, Ellen van der Spek, Carsten Utoft Niemann, Caspar da Cunha-Bang, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Barbara Eichhorst
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. American journal of hematology 99 (8) (2024)
Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Arnon Kater, Ellen van der Spek, Carsten Utoft Niemann, Caspar da Cunha-Bang, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Barbara Eichhorst
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. American journal of hematology (2024)
Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology 99 (6) (2024)
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Arnon P Kater, Ellen van der Spek, Carsten Utoft Niemann, Caspar da Cunha-Bang, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Barbara Eichhorst
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations. American journal of hematology 99 (8) (2024)
Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Fürstenau, Valentin Goede, Julia von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens M Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner J Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P Kater, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Othman Al-Sawaf
Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza, Eugen Tausch, Lothar Müller, Wolfgang Knauf, Matthias Zingerle, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Karl-Anton Kreuzer, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. American journal of hematology 99 (6) (2024)
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N Paulson, Christian P Pallasch, Lukas P Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nature communications 14 (1) (2023)
Othman Al-Sawaf, Matthew S Davids
Overcoming Resistance in Chronic Lymphocytic Leukemia - Maybe Less is More? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joe Paulson, Christian P Pallasch, Lukas P Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nature communications 14 (1) (2023)
Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Boettcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia von Tresckow, Ursula Vehling-Kaiser, Tobias Gaska, Clemens Martin Wendtner, Bjoern Chapuy, Kirsten Fischer, Karl-Anton Kreuzer, Stephan Stilgenbauer, Philipp Bernhard Staber, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial. Nature medicine (2023)
Othman Al-Sawaf, Jakob Weiss, Marcin Skrzypski, Jie Min Lam, Takahiro Karasaki, Francisco Zambrana, Andrew C Kidd, Alexander M Frankell, Thomas B K Watkins, Carlos Martínez-Ruiz, Clare Puttick, James R M Black, Ariana Huebner, Maise Al Bakir, Mateo Sokač, Susie Collins, Selvaraju Veeriah, Neil Magno, Cristina Naceur-Lombardelli, Paulina Prymas, Antonia Toncheva, Sophia Ward, Nick Jayanth, Roberto Salgado, Christopher P Bridge, David Chistopher Christiani, Raymond H Mak, Camden Bay, Michael Rosenthal, Naveed Sattar, Paul I Welsh, Ying Liu, Norbert Perrimon, Karteek Popuri, Mirza Faisal Beg, Nicholas McGranahan, Allan Hackshaw, Danna M Breen, Stephen I O'Rahilly, Nicolai Juul Birkbak, Hugo J W L Aerts, null null, Mariam Jamal-Hanjani, Charles Swanton
Body composition and lung cancer-associated cachexia in TRACERx. Nature medicine (2023)
Othman Al-Sawaf, Kirsten Fischer
TP53 mutations in CLL: does frequency matter? Blood 138 (25) (2022)
Othman Al-Sawaf, Brittany Gentile, Jacob Devine, Can Zhang, Kavita Sail, Maneesh Tandon, Anna-Maria Fink, Nadine Kutsch, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Hallek, Kirsten Fischer
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. American journal of hematology 96 (9) (2021)
Othman Al-Sawaf, Can Zhang, Tong Lu, Michael Z Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl-Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens-Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Othman Al-Sawaf, S Robrecht, J Bahlo, A M Fink, P Cramer, J V Tresckow, E Lange, M Kiehl, M Dreyling, M Ritgen, J Dürig, E Tausch, C Schneider, S Stilgenbauer, C M Wendtner, K Fischer, null Goede, M Hallek, B Eichhorst
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia 35 (1) (2020)
Carmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, Jasmin Bahlo, Sandra Robrecht, Petra Langerbeins, Anna-Maria Fink, Othman Al-Sawaf, Raymonde Busch, Raphael Porcher, Bruno Cazin, Brigitte Dreyfus, Stefan Ibach, Stéphane Leprêtre, Kirsten Fischer, Florian Kaiser, Barbara Eichhorst, Clemens-Martin Wentner, Manuela A Hoechstetter, Hartmut Döhner, Veronique Leblond, Michael Kneba, Remi Letestu, Sebastian Böttcher, Stephan Stilgenbauer, Michael Hallek, Vincent Levy
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia 34 (8) (2020)
Moritz Fürstenau, Georg Hopfinger, Sandra Robrecht, Anna-Maria Fink, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Julia Von Tresckow, Christian Maurer, Nadine Kutsch, Manuela Hoechstetter, Martin Dreyling, Elisabeth Lange, Michael Kneba, Stephan Stilgenbauer, Hartmut Döhner, Manfred Hensel, Michael G Kiehl, Ulrich Jaeger, Clemens-Martin Wendtner, Valentin Goede, Kirsten Fischer, Michael von Bergwelt-Baildon, Barbara Eichhorst, Michael Hallek, Sebastian Theurich
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia 34 (4) (2019)
Othman Al-Sawaf, P Köhler, D A Eichenauer, B Böll, M Kochanek, A Shimabukuro-Vornhagen
Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation. Annals of hematology 98 (3) (2019)
Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, Jasmin Bahlo, Craig Gower, Anna-Maria Fink, Julia Tresckow, Paula Cramer, Petra Langerbeins, Nadine Kutsch, Kathryn Humphrey, Günter Fingerle-Rowson, Stephan Stilgenbauer, Clemens-Martin Wendtner, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Valentin Goede
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American journal of hematology 94 (9) (2019)
Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Sandra Robrecht, Petra Langerbeins, Anna-Maria Fink, Othman Al-Sawaf, Thomas Illmer, Holger Klaproth, Sven Estenfelder, Matthias Ritgen, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara F Eichhorst, Michael Hallek
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia 33 (5) (2018)
Othman Al-Sawaf, Jasmin Bahlo, Sandra Robrecht, Kirsten Fischer, Carmen D Herling, Manuela Hoechstetter, Anna-Maria Fink, Julia von Tresckow, Petra Langerbeins, Paula Cramer, Stephan Stilgenbauer, Clemens M Wendtner, Barbara Eichhorst, Michael Hallek, Valentin Goede
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. British journal of haematology 183 (5) (2018)

Othman Al-Sawaf.css-eqlu8i{font-size:small;padding-left:4px;} (O Al-Sawaf)

Publication Activity (10 Years)

Top Topics

Top Venues

Othman Al-Sawaf (O Al-Sawaf)